ClinicalTrials.Veeva

Find clinical trials for Endometrial Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer
Ovarian Epithelial Carcinoma
Lung Cancer

Endometrial Cancer trials near New Haven, CT, USA:

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial...

Enrolling
Endometrial Cancer
Drug: IMGN853

Phase 2

Alessandro Santin

New Haven, Connecticut, United States

letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...

Active, not recruiting
Endometrial Cancer
Drug: Abemaciclib
Drug: Letrozole

Phase 2

Gynecologic Oncology Group (GOG)

New Haven, Connecticut, United States and 28 other locations

This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial c...

Active, not recruiting
Endometrial Cancer
Drug: Dostarlimab
Radiation: Intensity modulated radiation therapy (IMRT)

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

tumor response in patients with persistent, recurrent or metastatic endometrial cancer harboring an ultra-mutated or hyper-mutated ...

Active, not recruiting
Recurrent Endometrial Cancer
Drug: Pembrolizumab

Phase 2

Yale University
Yale University

New Haven, Connecticut, United States

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Enrolling
Endometrial Cancer
Ovary Cancer
Drug: STRO-002

Phase 1

Sutro Biopharma

New Haven, Connecticut, United States and 26 other locations

is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The re...

Enrolling
Endometrial Carcinosarcoma
Drug: Olaparib
Drug: Pembrolizumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects....

Active, not recruiting
Endometrial Adenocarcinoma
Endometrial Carcinosarcoma
Drug: BMS- 986205
Drug: Nivolumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic an...

Enrolling
Endometrial Carcinoma
Endometrial Cancer
Drug: Niraparib

Phase 2

Northwell Health
Northwell Health

Greenlawn, New York, United States and 4 other locations

drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

Phase 1

Lilly
Lilly

Commack, New York, United States and 75 other locations

choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...

Active, not recruiting
Endometrial Neoplasms
Drug: Pembrolizumab
Drug: Doxorubicin

Phase 3

Eisai
Eisai

New Haven, Connecticut, United States and 168 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems